- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Patent holdings for IPC class A61K 31/496
Total number of patents in this class: 11978
10-year publication summary
|
817
|
835
|
882
|
840
|
890
|
943
|
830
|
1010
|
1000
|
376
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10338 |
120 |
| Janssen Pharmaceutica N.V. | 3213 |
115 |
| The Regents of the University of California | 20590 |
110 |
| Boehringer Ingelheim International GmbH | 4494 |
105 |
| Otsuka Pharmaceutical Co., Ltd. | 1504 |
102 |
| Bristol-myers Squibb Company | 4789 |
84 |
| Merck Sharp & Dohme LLC | 3737 |
82 |
| Genentech, Inc. | 4090 |
72 |
| Alkermes Pharma Ireland Limited | 256 |
67 |
| Beyondspring Pharmaceuticals, Inc. | 85 |
66 |
| Board of Regents, The University of Texas System | 6065 |
63 |
| Arvinas Operations, Inc. | 258 |
63 |
| Takeda Pharmaceutical Company Limited | 2718 |
62 |
| Abbvie Inc. | 1837 |
59 |
| F. Hoffmann-La Roche AG | 7847 |
57 |
| Hoffmann-La Roche Inc. | 3726 |
56 |
| Centre National de La Recherche Scientifique | 10914 |
56 |
| Dana-Farber Cancer Institute, Inc. | 2645 |
53 |
| Astellas Pharma Inc. | 1035 |
52 |
| Celgene Corporation | 1392 |
52 |
| Other owners | 10482 |